Drugs / Hyalgan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00323778 | May 2006 → Sep 2007 | osteoarthritis, knee | Hospital for Special Surgery, New York | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00830830 | Dec 2005 → Oct 2006 | osteoarthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00130468 | Nov 2004 → May 2006 | osteoarthritis, knee | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT07373730 Comparator | Aug 2023 → Jun 2024 | temporomandibular joint disorder | Suez Canal University | Completed | No outcome recorded |
| — | NCT01760577 Comparator | May 2010 → May 2012 | osteoarthritis | Kaohsiung Veterans General Hospital. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyalgan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00323778 ↗ |
| Known as | sodium hyaluronate | “The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy).” NCT01760577 ↗ |